[go: up one dir, main page]

ATE230993T1 - Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält - Google Patents

Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält

Info

Publication number
ATE230993T1
ATE230993T1 AT99916907T AT99916907T ATE230993T1 AT E230993 T1 ATE230993 T1 AT E230993T1 AT 99916907 T AT99916907 T AT 99916907T AT 99916907 T AT99916907 T AT 99916907T AT E230993 T1 ATE230993 T1 AT E230993T1
Authority
AT
Austria
Prior art keywords
nmda receptor
receptor complex
pharmaceutical composition
opioid antagonists
alcohol dependence
Prior art date
Application number
AT99916907T
Other languages
English (en)
Inventor
Martine Daoust
Yves Le Buclay Bonhomme
Philippe Durbin
Original Assignee
Lipha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipha filed Critical Lipha
Application granted granted Critical
Publication of ATE230993T1 publication Critical patent/ATE230993T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99916907T 1998-03-26 1999-03-26 Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält ATE230993T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98400723A EP0945133A1 (de) 1998-03-26 1998-03-26 Pharmazeutische Zusammensetzung zur Behandlung von Alkohol- oder Drogenabhängigkeit, die Opioid Antagonisten mit NMDA-Rezeptorkomplex-Modulatoren enthält
PCT/EP1999/002337 WO1999048500A1 (en) 1998-03-26 1999-03-26 Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator

Publications (1)

Publication Number Publication Date
ATE230993T1 true ATE230993T1 (de) 2003-02-15

Family

ID=8235311

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99916907T ATE230993T1 (de) 1998-03-26 1999-03-26 Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält

Country Status (18)

Country Link
US (1) US6512009B1 (de)
EP (2) EP0945133A1 (de)
KR (1) KR20010034678A (de)
AT (1) ATE230993T1 (de)
AU (1) AU758569B2 (de)
BR (1) BR9909138A (de)
CA (1) CA2325739C (de)
CZ (1) CZ296367B6 (de)
DE (1) DE69904922T2 (de)
DK (1) DK1063995T3 (de)
ES (1) ES2190205T3 (de)
HK (1) HK1032542A1 (de)
HU (1) HU226555B1 (de)
NO (1) NO319313B1 (de)
PL (1) PL193241B1 (de)
RU (1) RU2226107C2 (de)
SK (1) SK284623B6 (de)
WO (1) WO1999048500A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1243543C (zh) * 1998-07-20 2006-03-01 派普泰克有限公司 生物植入物配方
US8052982B2 (en) 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
WO2001052851A1 (en) * 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
EP1262196A3 (de) * 2001-05-23 2002-12-18 Pfizer Products Inc. Kombination eines Inhibitoren der Monoaminwiederaufnahme und eines Opioidanatagonisten zur Verwendung in Alkoholismus und Alkoholsucht
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
ES2187288B1 (es) * 2001-09-24 2004-09-16 Garbil Pharma Investigacion Chile Ltda Aminas como agentes anti-alcoholismo.
AU2003240493B2 (en) * 2002-05-31 2008-06-12 L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Implantable polymeric device for sustained release of buprenorphine
CA2779723C (en) 2002-12-13 2014-03-25 Durect Corporation Oral drug delivery system
WO2004056337A2 (en) * 2002-12-18 2004-07-08 Pain Therapeutics Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
DE602004031512D1 (de) * 2003-03-31 2011-04-07 Titan Pharmaceuticals Inc Polymeres implantat zur verzögerten freisetzung von dopamin antagonisten
CA2526101A1 (en) * 2003-05-30 2004-12-23 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of nalmefene
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
MX2009006672A (es) * 2006-12-19 2009-10-26 Univ Virginia Efectos combinados de topiramato y ondansetron sobre el consumo de alcohol.
AU2008335809A1 (en) * 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
JP2011515076A (ja) 2008-02-28 2011-05-19 ユニバーシティ オブ バージニア パテント ファウンデーション セロトニン輸送体遺伝子およびアルコール中毒症の処置
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
SI2801625T1 (en) 2010-07-02 2018-04-30 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug addiction
WO2013036721A1 (en) 2011-09-09 2013-03-14 University Of Virginia Patent Foundation Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
RU2476209C1 (ru) * 2012-02-29 2013-02-27 Станислав Анатольевич Кедик Имплантируемое лекарственное средство на основе налтрексона для лечения пациентов, зависимых от алкоголя или опиатов
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
US20240350433A1 (en) * 2021-08-17 2024-10-24 Yale University Treatment compositions and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
WO1997033581A1 (en) * 1996-03-13 1997-09-18 Yale University Smoking cessation treatments using naltrexone and related compounds

Also Published As

Publication number Publication date
SK284623B6 (sk) 2005-08-04
EP1063995A1 (de) 2001-01-03
DE69904922T2 (de) 2004-01-08
RU2226107C2 (ru) 2004-03-27
SK14282000A3 (sk) 2001-05-10
HU226555B1 (en) 2009-03-30
WO1999048500A1 (en) 1999-09-30
HK1032542A1 (en) 2001-07-27
BR9909138A (pt) 2000-12-05
NO20004788L (no) 2000-11-24
US6512009B1 (en) 2003-01-28
HUP0101546A3 (en) 2002-10-28
CA2325739A1 (en) 1999-09-30
PL193241B1 (pl) 2007-01-31
CZ20003525A3 (cs) 2001-04-11
NO20004788D0 (no) 2000-09-25
AU3522699A (en) 1999-10-18
AU758569B2 (en) 2003-03-27
HUP0101546A2 (hu) 2001-09-28
DK1063995T3 (da) 2003-03-10
CZ296367B6 (cs) 2006-02-15
PL343069A1 (en) 2001-07-30
DE69904922D1 (de) 2003-02-20
KR20010034678A (ko) 2001-04-25
ES2190205T3 (es) 2003-07-16
EP0945133A1 (de) 1999-09-29
CA2325739C (en) 2007-05-15
EP1063995B1 (de) 2003-01-15
NO319313B1 (no) 2005-07-11

Similar Documents

Publication Publication Date Title
ATE230993T1 (de) Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält
NO960630D0 (no) Heterocykler anvendelige som neurokinin antagonister
ATE175114T1 (de) Pharmazeutische zusammensetzungen enthaltend einen opiat antagonist und calcium salze, ihre verwendung zur behandlung von endorphin- vermittelten krankheiten
DE69017302D1 (de) Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten.
ATE256463T1 (de) Pharmazeutische zubereitung zur verwendung in der behandlung von diabetes
DE69710095D1 (de) Pharmazeutische zubereitung zur behandlung von diabetes
ATE342728T1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
MA23608A1 (fr) Forme de dosage ii d'unite multiple en comprime
AR002459A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
ES2085337T3 (es) Comprimidos farmaceuticos.
ATE404211T1 (de) Xenon als nmda-antogonist zur neuroprotektion
BR0311898A (pt) Tratamento de associação para depressão e ansiedade com antagonistas de nk1 e nk3
ATE221391T1 (de) Konjugat enthaltend dtpa und albumin zur individuellen dosierung von arzneimitteln
PT101444A (pt) Associacao sinergizante com efeito antagonista dos receptores nk1 e nk2, uso de produtos com actividade antagonista dos receptores nk1 e nk2 na sua preparacao e composicao farmaceutica contendo a referida associacao
ATE400563T1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
DE60114597D1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
DK0648117T3 (da) Lægemiddel til at forebygge udvikling af tolerance ved behandling med benzodiazepin-receptor-bindende aktive forbindelser
BR0211323A (pt) Combinação de ingredientes ativos, uso de uma combinação de ingredientes ativos e método de terapia farmacológica de dependência de nicotina
BR0311881A (pt) Combinações de inbidores de pde-v e antagonistas de nk1 para o tratamento de depressão
EA200401617A1 (ru) Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера
ATE402178T1 (de) Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza- benzoäcüfluoren-6-carbonsäurederivate als nmda- antagonisten
RS49796B (sr) UPOTREBA SOLI 3α, 7α-DIHIDROKSI-12-KETO-5β-HOLANSKE KISELINE KAO AKTIVNE SUPSTANCE ZA IZRADU LEKOVA ZA LEČENJE DIJABETESA
BR0005039A (pt) Antagonistas do receptor nk-1 e eletriptano para o tratamento da enxaqueca
DE68905343D1 (de) Dosisform zur verabreichung von calciumantagonisten.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1063995

Country of ref document: EP